Notice Number: NOT-NS-08-024
Release Date: September 18, 2008
Response Due By: November 26, 2008
National Institute of Neurological Disorders and Stroke (NINDS) http://www.ninds.nih.gov
The National Institute of Neurological Disorders and Stroke (NINDS) is considering developing a medicinal chemistry program for therapy development. The goal of the program would be to develop lead compounds with sufficient potency, efficacy, and drug-likeness to begin the preclinical pharmacology and safety (ADMET) studies required for an investigational new drug (IND) application. The NINDS envisions awarding a contract for medicinal chemistry services. These services would be available to researchers who have small molecule compounds that show promise for treating neurological conditions but who cannot yet attract private sector investment. The Institute is exploring the interest in such a resource and seeks feedback on its structure from both potential contractors and potential users.
High-throughput screens and basic research studies have led to the discovery of many small molecule compounds with activity in models of neurological disease. Some of these compounds might be transformed into drugs, with chemical modifications to improve their potency and pharmacological properties. However, biotechnology and pharmaceutical companies are hesitant to invest in the early development of compounds for rare diseases or new targets, given concerns about profitability and risk. Academic researchers who have identified a promising compound rarely have access to medicinal chemistry services. The NINDS is considering a medicinal chemistry program to overcome these barriers to drug development. This program is envisioned as a collaborative effort between a medicinal chemistry service facility and researchers with bioassays that model neurological disorders and a bioactive small molecule compound.
The medicinal chemistry facility would provide:
Users of the facility would provide:
Potential users from the research community could apply for access to these medicinal chemistry services. Applications would be reviewed with rapid turn-around. Consultants with medicinal chemistry and drug development expertise would oversee the program and provide guidance on individual projects. The medicinal chemistry facility and consultants would assist users with preliminary studies to determine if the starting compound is amenable to chemical optimization. For the most promising compounds, the medicinal chemistry facility would conduct rapid, iterative rounds of analog synthesis and testing in close collaboration with the user. Typically, compounds would be tested on a weekly or biweekly schedule, with results of the primary screening informing the subsequent compound design and synthesis by the medicinal chemists. If requested, this work could be done confidentially. Facility users would conduct all of the tests involving disease-specific assays and models in their own laboratories.
The user would be expected to continue the development of lead compounds generated by the medicinal chemistry facility and facilitate their transition into clinical testing. The user may seek support for follow-up studies through the NINDS Cooperative Program in Translational Research (http://grants.nih.gov/grants/guide/pa-files/PAR-08-232.html) or NIH RAID (http://nihroadmap.nih.gov/raid/).
This Request for Information (RFI) seeks input on the design of this program both from potential medicinal chemistry service contractors and from potential users of these services. Please respond to one or both of the sections below, based on your interest in this program.Information Requested from Potential Contractors
If you would be interested in competing for a contract to provide medicinal chemistry and lead optimization services to the NINDS and members of the NINDS research community, please provide the following information in no more than five (5) pages:
Information Requested from Potential Users
If you anticipate having compound(s) for optimization, your input on any or all of following issues is appreciated. Please limit your response to a maximum of three (3) pages.
This Request for Information (RFI) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The Government does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted or the Government’s use of such information. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the Government’s evaluation of the information received. However, should such a requirement materialize, no basis for claims against the Government shall arise as a result of a response to this request for information or the Government’s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. Responses will be held in a confidential manner. Any proprietary information should be so marked.
All respondents are asked to indicate the type and size of your business organization, e.g., Large Business, Small Business, Veteran-Owned Small Business, Service-Disabled Veteran-Owned Small Business, HUBZone Small Business, Small Disadvantaged Business, Women-Owned Business, 8(a), Historically Black College or University/Minority Institution (HBCU/MI), educational institution, profit/non-profit hospital, or other nonprofit organization.
Responses should be identified with NINDS RFI NS-08-024 and are due by November 26, 2008. Please submit two (2) copies of your response to:
NINDS R&D Contracts Management Branch
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3287, MSC 9531
Bethesda, Maryland 20892-9531
(for FedEx or courier, use: Rockville, MD 20852)
Phone Number: 301-496-1813
Fax Number: 301-402-4225
E-mail responses sent to email@example.com will also be accepted.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)